Ixchiq Disease Interactions
There is 1 disease interaction with Ixchiq (chikungunya vaccine, live (cvx 317)).
Moderate
Vaccines (live attenuated/toxoid) (applies to Ixchiq) immunocompromised
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Immunodeficiency
The expected antibody responses may not be obtained when live attenuated vaccines and/or toxoids are administered to immunosuppressed persons, including those receiving immunosuppressive therapy. Caution and close monitoring is advised.
References
- (2005) "Product Information. Menactra (meningococcal conjugate vaccine)." sanofi pasteur
- (2022) "Product Information. ActHIB (Hib) (haemophilus b conjugate (PRP-T) vaccine)." sanofi pasteur
- (2022) "Product Information. Bexsero (meningococcal group B vaccine)." Novartis Vaccines & Diagnostics Inc
- (2022) "Product Information. Trumenba (meningococcal group B vaccine)." Pfizer U.S. Pharmaceuticals Group
- (2022) "Product Information. Hiberix (Hib) (haemophilus b conjugate (PRP-T) vaccine)." GlaxoSmithKline
- (2016) "Product Information. Vaxchora (cholera vaccine, live)." PaxVax
- (2022) "Product Information. Vaxchora (cholera vaccine, live)." Emergent Travel Health, Inc
- (2023) "Product Information. Ixchiq (cvx 317) (chikungunya vaccine, live (cvx 317))." Valneva USA
Ixchiq drug interactions
There are 315 drug interactions with Ixchiq (chikungunya vaccine, live (cvx 317)).
More about Ixchiq (chikungunya vaccine, live (cvx 317))
- Ixchiq consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- FDA approval history
- Drug class: viral vaccines
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.